Michael J. Fox Foundation Expands its Biomarker Clinical Study

As the founder and CEO of New York-based Consonance Capital, Mitchell Blutt manages the healthcare investment firm’s hedge funds and private equity funds. A philanthropic individual, Mitchell Blutt served as a board member of the Michael J. Fox Foundation, which helps those affected by Parkinson’s disease. Established in 2000, the Foundation is the largest non-profit organization focusing on Parkinson’s disease, and has raised more than $350 million.

In 2010, the foundation created a five-year biomarker clinical study, entitled the Parkinson’s Progression Markers Initiative (PPMI), to study the imaging, clinical, and biological data associated with the disease. The foundation dedicated $45 million to this endeavor and recruited individuals to participate in the trial. In February 2014, the foundation announced that it is seeking additional participants who possess genetic mutations associated with the disease. The overall goal is to make a connection between the onset of the disease and having the gene LRRK2 mutation. This gene is the most common genetic contributor to the disease. Those who meet the qualifications may receive genetic counseling through the PPMI and the Foundation.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s